Will Ozempic Cost More in 2026? Drug Tariff Impact Explained
Ozempic's price could rise by 30-100% after the July 31, 2026 pharmaceutical tariff. Here's exactly how much you'll pay and whether switching to Mounjaro makes sense.
Ozempic is the most-prescribed GLP-1 medication in the United States. With the April 2, 2026 Presidential Proclamation imposing a 100% tariff on imported brand-name pharmaceuticals effective July 31, 2026, millions of patients are asking: will Ozempic cost more? The short answer is yes — Ozempic is manufactured by Novo Nordisk in Denmark, so it falls squarely within the tariff's scope. Here's exactly what to expect, and whether alternatives like Mounjaro make financial sense.
The Ozempic Tariff Picture at a Glance
| Fact | Detail |
|---|---|
| Manufacturer | Novo Nordisk |
| Manufacturing country | Denmark |
| Tariff applies? | Yes (Novo Nordisk is Annex III company) |
| Effective date | July 31, 2026 |
| Tariff rate | 100% on wholesale import cost |
| Current US retail (monthly) | ~$968 |
| Projected retail after tariff | $1,258 to $1,936 (depending on passthrough) |
Why Ozempic Is Affected
The 100% pharmaceutical tariff applies based on where a drug is manufactured, not where the company is headquartered. Ozempic is manufactured at Novo Nordisk's production facilities in Denmark (primarily Kalundborg) and filled into pens in Hillerød, Denmark. Every Ozempic injector sold in the US is imported.
Novo Nordisk is explicitly listed in Annex III of the proclamation, meaning Ozempic faces the tariff 60 days earlier than non-Annex III drugs — on July 31, 2026 rather than September 29, 2026.
Three Price Scenarios for Ozempic After July 31
The tariff applies to wholesale import cost, not retail. For Ozempic, wholesale cost is approximately 25-35% of retail. Industry analysts expect Novo Nordisk to pass through some but not all of the tariff to retail prices. Here are the three most likely scenarios:
| Scenario | Passthrough | New Monthly Retail | Annual Cost |
|---|---|---|---|
| Conservative | 25% | $1,258 | $15,100 |
| Likely | 50% | $1,452 | $17,420 |
| Worst case | 100% | $1,936 | $23,230 |
Current annual cost: $11,616 Projected annual increase: $3,484 (conservative) to $11,614 (worst case)
For a patient paying out-of-pocket, that's between $290 and $967 more per month.
What About Insurance?
Most insurance plans currently cover Ozempic for type 2 diabetes (its FDA-approved indication) with a typical copay of $25-50/month. Weight loss use is generally not covered unless the specific plan covers it.
What's likely to happen after July 31:
| Change | Likelihood | Impact |
|---|---|---|
| Drug removed from formulary | Low | Would trigger patient backlash; insurers likely keep it on |
| Moved to higher formulary tier | High | Copay increases from ~$25 to $50-100 or coinsurance |
| Prior authorization added or tightened | High | More paperwork, potential denials |
| Coinsurance (% of cost) instead of flat copay | Moderate | Patient pays % of higher wholesale price |
Expect your out-of-pocket cost to rise by $15-50/month even with good insurance.
Should You Switch to Mounjaro or Zepbound?
Mounjaro (tirzepatide) and its weight-loss sibling Zepbound are made by Eli Lilly in Indiana and North Carolina — they are US-manufactured and exempt from the tariff.
Clinical differences:
| Dimension | Ozempic (Semaglutide) | Mounjaro (Tirzepatide) |
|---|---|---|
| Indication | Type 2 diabetes (primary), weight loss (off-label) | Type 2 diabetes (primary) |
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Weight loss efficacy | Moderate | Higher (typically more weight loss) |
| A1C reduction | 1.4-1.8% | 1.7-2.1% |
| Dosing | Once weekly | Once weekly |
| Side effects | Similar (nausea, GI effects) | Similar |
| Current US retail | ~$968 | ~$1,069 |
| Post-tariff retail (likely) | $1,452 | $1,069 (unchanged) |
The math favors switching if your doctor agrees it's clinically appropriate. After the tariff takes effect, Mounjaro will be approximately $383/month cheaper than Ozempic (likely scenario) — a $4,600/year difference.
How to Switch
- Talk to your doctor about whether Mounjaro or Zepbound is clinically suitable for you
- Check your insurance formulary — Mounjaro may be on a different tier than Ozempic
- Consider the side effect profile — some patients tolerate one better than the other
- Request a prescription change — typically a simple e-prescription update
- Expect a titration period — starting doses are different; your doctor will manage
Other Ozempic Alternatives
| Alternative | Tariff Status | Notes |
|---|---|---|
| Mounjaro (tirzepatide) | Exempt (US-made) | Similar mechanism, possibly superior efficacy |
| Zepbound (tirzepatide) | Exempt (US-made) | Same molecule as Mounjaro, indicated for weight loss |
| Trulicity (dulaglutide) | Exempt (US-made) | Older GLP-1, less weight loss than Ozempic |
| Bydureon (exenatide) | Exempt (US-made) | Older GLP-1, weekly, less effective |
| Victoza (liraglutide) | Affected (Denmark) | Older Novo Nordisk GLP-1, daily injection |
| Saxenda (liraglutide) | Affected (Denmark) | Same molecule as Victoza, indicated for weight loss |
| Metformin (generic) | Exempt (generic) | First-line diabetes drug; no weight loss benefit |
Can Ozempic Be Stockpiled Before the Tariff?
Most insurance plans allow a 90-day supply for maintenance medications. Check with your insurer about their early refill policy:
- Standard: 30-day supply, refill when 25% remaining
- Mail order: 90-day supply available for maintenance drugs
- Some plans allow "vacation overrides" for up to 30 additional days
You cannot refill more than your prescription allows. If you're on a 30-day supply, you can't get 6 months at once. But switching to a 90-day mail-order prescription before June 2026 locks in today's price for 90 days into the tariff period.
Check with your insurance about early refill policies and 90-day supply eligibility for your specific plan.
Will Novo Nordisk Sign a Deal?
The White House has signaled that pharmaceutical companies can avoid or reduce the tariff by signing pricing and onshoring deals:
- Lowering US list price to Most-Favored-Nation (MFN) reference levels
- Committing to build or expand US manufacturing
- Accepting volume commitments or pricing transparency
Novo Nordisk has publicly stated it is in negotiations with the administration. A deal could:
- Reduce or eliminate the tariff on Ozempic/Wegovy
- Lower US list prices (potentially below current levels)
- Accelerate US manufacturing (Novo has announced a North Carolina facility expansion)
As of this article's publication, no deal has been finalized. Plan as if the tariff will take effect on July 31, 2026.
Medicare Part D and Ozempic
Ozempic is not currently on the Medicare-negotiated drug price list for 2026. However:
- Medicare Part D insulin is capped at $35/month regardless of tariff
- Medicare's out-of-pocket maximum is $2,000/year starting 2025
- Ozempic is expected to be selected for Medicare negotiation in upcoming rounds
If you're on Medicare, your out-of-pocket exposure is limited to $2,000/year across all Part D drugs combined. The tariff may still impact your premium.
Frequently Asked Questions
Is Wegovy also affected by the tariff?
Yes. Wegovy is the same molecule (semaglutide) as Ozempic, made by Novo Nordisk in Denmark. It faces the same 100% tariff on July 31, 2026. Current retail is ~$1,349/month; projected post-tariff likely case is ~$2,024/month.
Why is Mounjaro exempt if Ozempic isn't?
Mounjaro is manufactured by Eli Lilly at facilities in Indianapolis and Durham (North Carolina). The tariff applies based on country of manufacture. US-made drugs are exempt; drugs made abroad are affected.
What if Ozempic was on back-order or I had to get it from Canada?
Personal importation of prescription drugs from Canada is legally restricted by the FDA. The agency has historically exercised discretion for 90-day supplies of non-controlled medications for personal use. The tariff applies at the US port of entry. Consult a licensed pharmacist before ordering from abroad.
How accurate are these price projections?
Projections are based on the 100% tariff rate, typical brand pharma wholesale cost margins (~25-35% of retail), and historical industry passthrough norms (25-75% of input cost shocks). Actual prices will depend on Novo Nordisk's pricing decisions, insurance formulary changes, PBM negotiations, and whether Novo Nordisk signs a deal with the administration. Use TariffCheck for updated estimates as more information becomes available.
When should I talk to my doctor about switching?
Now. If you're considering switching to Mounjaro or another alternative, start the conversation in April or May 2026. Switching takes time — new prescription, insurance prior authorization, titration to effective dose. Don't wait until August to start the process.
Conclusion
Ozempic will almost certainly cost more after July 31, 2026 — likely $1,258 to $1,936 per month vs. ~$968 today. For patients with good insurance, the copay impact may be manageable ($15-50/month increase). For the uninsured or those paying out-of-pocket, the tariff could add $290-967/month. Switching to US-made Mounjaro saves $4,600+/year and is clinically viable for most diabetes patients. Talk to your doctor early, and check your specific medication's impact here.